Z Factor

Z Factor Limited is a drug discovery company established in 2015, focusing on developing therapeutic agents for alpha-1-antitrypsin deficiency. Founded through a collaboration between Index Ventures and the University of Cambridge, the company aims to design innovative treatments that correct the misfolding of the Z variant of alpha-1-antitrypsin. This condition currently has limited treatment options, primarily relying on lung or liver transplantation and augmentation therapy. Z Factor's mission addresses a significant unmet medical need by working to create effective alternatives for patients suffering from this deficiency.